Luteinizing hormone-releasing hormone peptide tethered nanoparticulate system for enhanced antitumoral efficacy of paclitaxel

Nanomedicine

Volumn 11, Issue 7, 2016, Pages 797-816

  Ghanghoria, Raksha ^a   Tekade, Rakesh Kumar ^b,c   Mishra, Anil Kumar ^d   Chuttani, Krishna ^d   Jain, Narendra Kumar ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^d INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

biodistribution; cancer targeting; LHRH; paclitaxel; pharmacodynamics; pharmacokinetics; PLGA copolymer

Indexed keywords

GONADORELIN; LEUTINIZING HORMONE RELEASING HORMONE TETHERED POLY(LACTIC CO GLYCOLIC ACID) COPOLYMER POLY ETHYLENE GLYCOL NANOPARTICLE; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; LACTIC ACID; MACROGOL DERIVATIVE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; SYNTHESIS; ANIMAL; BREAST; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; FEMALE; MCF-7 CELL LINE; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST; BREAST NEOPLASMS; DRUG CARRIERS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LACTIC ACID; MCF-7 CELLS; MICE, NUDE; NANOPARTICLES; PACLITAXEL; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID;

EID: 84962052421     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.16.19     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J. Clin. 64, 9-29 (2014
2. Munaron L. Systems biology of ion channels and transporters in tumor angiogenesis: an omics view. Biochim. Biophys. Acta 1848, 2647-2656 (2015
3. Tekade RK, Youngren-Ortiz SR, Yang H, Haware R, Chougule MB. Designing hybrid onconase nanocarriers for mesothelioma therapy: a Taguchi orthogonal array and multivariate component driven analysis. Mol. Pharm. 11, 3671-3683 (2014
4. TekaDeRK, TekaDeM, Kumar M, Chauhan AS. Dendrimerstabilized smart-nanoparticle (DSSN) platform for targeted Delivery of hydrophobic antitumor therapeutics. Pharm. Res. 32, 910-928 (2015
5. Hashizume H, Baluk P, Morikawa S, et al. Openings between Defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156(4), 1363-1380 (2000
6. Gandhi NS, TekaDeRK, Chougule MB. Nanocarrier mediated Delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J. Control. Rel. 194, 238-256 (2014
7. Thakur S, TekaDeR, Kesharwani P, Jain N. The effect of polyethylene glycol spacer chain length on the tumortargeting potential of folate-modified PPI Dendrimers. J. Nanoparticle Res. 15, 1-16 (2013
8. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptiDeconjugates to their receptors on tumors. Eur. J. Endocrinol. 141, 1-14 (1999
9. Tolkach Y, Joniau S, Van Poppel H. Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?. BJU Int. 111, 1021-1030 (2013
10. Kwok CW, Treeck O, Buchholz S, Seitz S, Ortmann O, Engel JB. Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). Target Oncol. 10, 365-373 (2015
11. Gründker C, Ernst J, Reutter MD, Ghadimi BM, Emons G. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers. Oncol. Rep. 26, 629-635 (2011
12. Grundker C, Gunthert AR, Millar RP, Emons G. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J. Clin. Endocrinol. Metab. 87, 1427-1430 (2002
13. Recchia F, Necozione S, Bratta M, Rosselli M, Guerriero G, Rea S. LH-RH analogues in the treatment of young women with early breast cancer: long-Term follow-up of a Phase II study. Int. J. Oncol. 46, 1354-1360 (2015
14. Dharap SS, Qiu B, Williams GC, Sinko P, Stein S, Minko T. Molecular targeting of drug Delivery systems to ovarian cancer by BH3 and LHRH peptiDes. J. Control. Release 91, 61-73 (2003
15. Emons G, Gorchev G, Sehouli J, et al. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter Phase II trial of the ago-study group (AGO GYN 5). Gynecol. Oncol. 133, 427-432 (2014
16. Saad M, Garbuzenko OB, Ber E, et al. Receptor targeted polymers, Dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?. J. Control. Release 130, 107-114 (2008
17. Sundaram S. Durairaj C, Kadam R, Kompella UB. Luteinizing hormone-releasing hormone receptor-Targeted Deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol. Cancer Ther. 8(6), 1655-1665 (2009
18. Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell Death induction in ovarian cancer: an optimal Delivery of siRNA and anticancer drug. Clin. Cancer Res. 15, 6193-6204 (2013).
19. Ilinskaya AN, Clogston JD, McNeil SE, Dobrovolskaia MA. Induction of oxidative stress by Taxol® vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring Denovo synthesis of mRNA. Nanomedicine 11, 1925-1938 (2015
20. Li M, Liu Y, Feng L, Liu F, Zhang L, Zhang N. Polymeric complex micelles with double drug-loading strategies for folate-mediated paclitaxel Delivery. Colloids Surf. B Biointerfaces 1, 191-201 (2015
21. Yadav AK, Mishra P, Mishra AK, Mishra P, Jain S, Agrawal GP. Development and characterization of hyaluronic acid-Anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine 3, 246-257 (2007
22. Fessi H, Puisieux F, Devissaguet JPh, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer Deposition following solvent displacement. Int. J. Pharm. 55(1), R1-R4 (1989
23. Beletsi A, Panagi Z, Avgoustakis K. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int. J. Pharm. 298, 233-241 (2005
24. Yang T, Choi MK. Preparation and evaluation of paclitaxelloaDed PEGylated immunoliposome, J. Control. Release 120, 169-177 (2007
25. Tekade RK, Dutta T, Gajbhiye V, Jain NK. Exploring Dendrimer towards dual drug Delivery: pH responsive simultaneous drug-release kinetics. J. Microencap. 26, 287-296 (2009
26. Mody N, Tekade RK, Mehra NK, ChopDey P, Jain NK. Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: one platform assessment of drug Delivery potential. AAPS PharmSci Tech. 15, 388-399 (2014
27. Youngren SR, Tekade RK, Gustilo B, Hoffmann PR, Chougule MB. STAT6 siRNA matrix-loaDed gelatin nanocarriers: formulation, characterization, and ex vivo proof of concept using aDenocarcinoma cells. Biomed. Res. Int. 2013, 858946 (2013
28. Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RS. Influence of administration route on tumor uptake and biodistribution of etoposiDeloaDed solid lipid nanoparticles in Daltons lymphoma tumor bearing mice. J. Control. Release. 105(3), 185-198 (2005
29. Mishra AK, Iznaga-Escobar N, Figueredo R, et al. Preparation and comparative evaluation of 99mTc-labeled 2 iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF receptor antibodies. Methods Find. Exp. Clin. Pharmacol. 24, 653-660 (2002
30. Upadhyay KK, Bhatt AN, Castro E, et al. In vitro and in vivo evaluation of docetaxel loaDed bioDegradable polymersomes. Macromol. Biosci. 10, 503-512 (2010
31. Zhang G, Yang Z, Lu W, et al. Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials 30, 1928-1936 (2009
32. Liu Z, Chen K, Davis C, et al. Drug Delivery with carbon nanotubes for cancer treatment. Cancer Res. 68(16), 6652-6660 (2008
33. Stevanovic MM, Jordovic B, Uskokovic DP. Preparation and characterization of poly(d, l lactiDe-co-glycoliDe) microparticles containing ascorbic acid. J. Biomed. Biotechnol. 2007(7), 84965 (2007
34. Dong Y, Feng SS. Methoxy poly (ethylene glycol)-poly (lactiDe) (MPEG-PLA) nanoparticles for controlled Delivery of anticancer drugs. Biomaterials 25, 2843-2849 (2004
35. Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-Delivery of anticancer drugs and siRNA. J. Control. Release 171, 349-357 (2013
36. Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell Death induction in ovarian cancer: an optimal Delivery of siRNA and anticancer drug. Clin. Cancer Res. 19, 6193-6204 (2013
37. Konan YN, Gurney R, Allemann E. Preparation and characterization of sterile and freeze dried sub-200 nm nanoparticles. Int. J. Pharm. 233, 239-252 (2002
38. Wang YM, Sato H, Horikoshi I. In vitro and in vivo evaluation of taxol release from poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate and Degradation of the microspheres. J. Control. Release 49, 157-166 (1997
39. Liebmann J, Cook JA, Mitchell JB. Cremophor EL, solvent for paclitaxel, and toxicity. Lancet 342, 1428 (1993
40. Sugahara S, Kajiki M, Kuriyama H, Kobayashi TR. Paclitaxel Delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethylDextran to create prodrugs. Biol. Pharm. Bull. 25, 632-641 (2002